Navigation Links
Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions
Date:7/28/2014

HONG KONG, July 28, 2014 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today that its new PicoWay® device has received CE Mark indication to treat tattoos of all types and colors and pigmented lesions on any skin type. PicoWay is a new and innovative dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes Syneron's proprietary PicoWay technology to deliver energy to the skin using pulses which are trillionths of a second, known as picosecond pulses. Syneron will begin a staged launch of the PicoWay device in the international market during the third quarter of 2014 and anticipates that it will receive U.S. Food and Drug Administration (FDA) clearance for PicoWay by the end of 2014.

PicoWay's high peak power and ultra-short pulse duration enable a unique mode of action which creates the strongest photo-mechanical impact to break up the tattoo ink or the pigmentation. This revolutionary PicoWay technology is integrated into a proven, reliable Candela® platform which ensures superior performance and low cost of ownership.

"Our investment in PicoWay's research and development demonstrate Syneron's commitment to develop technology that enables physicians to provide best-in-practice treatments for their patients," stated Amit Meridor, CEO of Syneron. "Since PicoWay has the shortest picosecond pulse duration and the highest peak power of any device on the market, we believe that fewer treatments will be needed and that the percentage clearance will be higher. We are pleased that Dr. Chan will present his positive results with PicoWay at IMCAS Asia, particularly because it will be a significant market for PicoWay due to the special value placed on clear skin in Asia."

Dr. Henry Chan, specialist in dermatology in Hong Kong, will present the interim results of a multi-center study focused on treating pigmented lesions with PicoWay at the IMCAS Asia Conference slated for August 1-3, 2014 in Hong Kong. His presentation is entitled "The Use of Picosecond Lasers on Asians".

Dr. Chan says "PicoWay's unique mode of picosecond action enables full flexibility to adjust the wavelength, fluence, spot size and rep rate, providing customizable treatments which ensure outstanding clinical results. The novel PicoWay technology enables our clinic to offer a new and exciting solution to remove pigmented lesions. The treatments have proven to be effective, safe and comfortable with a high satisfaction rate among our patients."

About Syneron
Syneron Medical Ltd. is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint.  The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch.  

Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the U.S.  The company markets, services and supports its products in 86 countries.  It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

For additional information, please visit http://www.syneron-candela.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, treatment results, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions, market acceptance of new products, and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical makes with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.  These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Additional information can be found at www.syneron-candela.com

Contacts:
Zack Kubow, The Ruth Group, zkubow@theruthgroup.com, 646-536-7020
Hugo Goldman, Chief Financial Officer, Syneron, Hugo.Goldman@syneron.com
Syneron Medical Public Relations
 pr@syneron.com

Logo - http://photos.prnewswire.com/prnh/20120528/535447


'/>"/>
SOURCE Syneron Medical Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Syneron Medical And Unilever Ventures Create Iluminage Beauty, A Global Joint Venture In Home Beauty Devices
2. Synerons elure Brings Home Allure Magazines Best of Beauty Award, for the Third Consecutive Year
3. Syneron Medical stellt die nächste Generation von Handstücken für die Haarentfernung mit Gentle Pro Laser und elos-Plus-Systemen vor
4. Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy
5. Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com
6. IDEXX Laboratories Announces Second Quarter Results
7. IRIDEX Announces Second Quarter 2014 Conference Call and Release Date
8. Amgen Announces Webcast of 2014 Second Quarter Financial Results
9. IGI Laboratories, Inc. Announces Change To Its Board Of Directors
10. IGI Laboratories Announces Second Quarter 2014 Results
11. DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Association, in partnership with ALS Finding a Cure, is pleased ... track TDP43 aggregation. The successful team(s) with the most developed ... --> --> ALS is ... brain and the spinal cord. Eventually, people with ALS lose ... leads to total paralysis and death within two to five ...
(Date:2/10/2016)... Feb. 10, 2016 Convergence scenarios ... of various technologies that results in diverse ... These opportunities create a cyclical system where ... drives the development of new technologies. ... by technology convergences, which are constantly fostering ...
(Date:2/10/2016)... 10, 2016 Antibacterial Drugs Market - ... - 2023 ", reveals that the global antibacterial drugs market ... to 2023 owing to patent expiries of blockbuster drugs. Even ... during the forecast period, the value is anticipated to decline ... --> Antibacterial Drugs Market - Global Industry Analysis, ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing ... February 2016. Each webinar features a dynamic expert and thoughtful presentation to give ... patients and facilities. Both events are free to attend, but registration is ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... American Academy of Emergency Medicine , an emergency medicine professional association, ... practice management services . , The American Academy of Emergency Medicine, or AAEM, ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency in ... assist the local community. Pledging to select a new beneficiary every 60 days, ... area. Their goal is to bring community awareness to important local causes by ...
(Date:2/10/2016)... , ... February 10, 2016 , ... 10 Best ... There were three leading bottled water brand owners that topped the list as a ... connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch water ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of ... is now accepting new dental patients and families in the North Metro Denver area. ... services from cleanings to cosmetic dentistry, and all in the most relaxing environment. , ...
Breaking Medicine News(10 mins):